Longterm Followup Assessment of a HER2/neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients

Journal of the American College of Surgeons

Volumn 208, Issue 2, 2009, Pages 193-201

  Gates, Jeremy D ^a   Carmichael, Mark G ^b,c   Benavides, Linda C ^a   Holmes, Jarrod P ^d   Hueman, Matthew T ^b   Woll, Michael M ^b   Ioannides, Constantine G ^e   Robson, Craig H ^f   McLeod, David G ^c   Ponniah, Sathibalan ^b   Peoples, George E ^a,b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b United States Military Cancer Institute   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; LYSYLISOLEUCYLPHENYLALANYLGLYCYLSERYLLEUCYLALANYLPHENYLALANYLLEUCINE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; MALE; OPERATION DURATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; CANCER VACCINES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 58249108159     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2008.10.018     Document Type: Article

References (38)

1. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
2. Signoretti S., Montironi R., Manola J., et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92 (2000) 1918-1925
3. Hueman M., Dehqanzada Z., Novak T., et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 11 (2005) 7470-7479
4. Anderson B.W., Peoples G.E., Murray J.L., et al. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res 6 (2000) 4192-4200
5. Lustgarten J., Theobald M., Labadie C., et al. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD. 8. Hum Immunol 52 (1997) 109-118
6. Zaks T.Z., and Rosenberg S.A. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58 (1998) 4902-4908
7. Knutson K.L., Schiffman K., Cheever M.A., et al. Immunization of cancer patients with HER-2/neu, HLA-A2 peptide, p369-377, results in shortlived peptide-specific immunity. Clin Cancer Res 8 (2002) 1014-1018
8. Woll M.M., Hueman M.T., Ryan G.B., et al. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. Int J Oncol 25 (2004) 1769-1780
9. Ross J.S., Sheehan C.E., Hayner-Buchan A.M., et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79 (1997) 2162-2170
10. Skacel M., Ormsby A.H., Pettay J.D., et al. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum Pathol 32 (2001) 1392-1397
11. Murray J.L., Gillogly M.E., Przepiorka D., et al. Toxicity, immunogenicity, and induction of E75-specific tumorlytic CTLs by HER-2 peptide E74 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8 (2002) 3407-3418
12. Morrison C., Zanagnolo V., Ramirez N., et al. HER-2 is an independent prognositic factor in endometrial cancer: association with outcome in a large cohort of surgically stage patients. J Clin Oncol 24 (2006) 2376-2385
13. Fisk B., Blevins T.L., Wharton J.T., et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181 (1995) 2109-2117
14. Garin-Chesa P., Campbell I., Saigo P.E., et al. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 142 (1993) 557-567
15. Alberti S., Miotti S., Fornano M., et al. The CA-MOv18 molecule, a cell surface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositol. Biochem Biophys Res Commun 171 (1990) 1051-1055
16. Jacob J.A. Folate, DNA methylation, and gene expression: factors of nature and nurture. Am J Clin Nutr 72 (2000) 903-904
17. Li P.Y., Del Vecchio S., Fonti R., et al. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. J Nucl Med 37 (1996) 665-672
18. Weitman S.D., Lark R.H., Coney L.R., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52 (1992) 3396-3401
19. Amin A., Benavides L.C., Holmes J.P., et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventative HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother (2008) Epub ahead of print
20. Bauer J.J., Connelly R.R., Sesterhenn I.A., et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 159 (1998) 929-933
21. Moul J.W., Connelly R.R., Lubeck D.P., et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 166 (2001) 1322-1327
22. Ellis J.M., Henson V., Slack R., et al., Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance of A*02011 and identification of HLA-A*0231. Hum Immunol 61 (2000) 334-340
23. Sokal J.E. Measurement of delayed skin-test responses. N Engl J Med 293 (1975) 501-502
24. Holmes J.P., Gates J.D., Benavides L.C., et al. Optimal dose and schedule of a HER2/neu (E75) peptide vaccine to prevent breast cancer recurrence: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer (2008) Epub ahead of print
25. Lee J.E. Factors associated with melanoma incidence and prognosis. Semin Surg Oncol 12 (1996) 379-385
26. Lee J.E., Lowy A.M., Thompson W.A., et al. Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology 111 (1996) 426-432
27. De Petris L., Bergfeldt K., Hising C., et al. Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 21 (2004) 49-52
28. Craft N., Shostak Y., Carey M., et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 (1999) 280-285
29. Berger R., Lin D.I., Nieto M., et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66 (2006) 5723-5728
30. Osman I., Scher H.I., Drobnjak M., et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7 (2001) 2643-2647
31. Morris M.J., Reuter V.E., Kelly W.K., et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 94 (2002) 980-986
32. Nishio Y., Yamada Y., Kokubo H., et al. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 68 (2006) 110-115
33. Mellinghoff I.K., Vivanco I., Kwon A., et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA bind and stability. Cancer Cell 6 (2004) 517-527
34. Ziada A., Barqawi A., Glode L.M., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60 (2004) 332-337
35. de Bono J.S., Bellmunt J., Attard G., et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone-refractory prostate cancer. J Clin Oncol 25 (2007) 257-262
36. Webster W.S., Small E.J., Rini B.I., et al. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 23 (2005) 8262-8269
37. Sonpavde G., Spencer D.M., Slawin K.M., et al. Vaccine therapy for prostate cancer. Urologic Oncology 25 (2007) 451-459
38. Finn O.J. Molecular origins of cancer: cancer immunology. N Engl J Med 358 (2008) 2704-2715